Vadodara, India

Gulamnizami Abdulsattar Qureshi

USPTO Granted Patents = 1 

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Gulamnizami Abdulsattar Qureshi: Innovator in Malic Enzyme Inhibitors**

Introduction

Gulamnizami Abdulsattar Qureshi is a notable inventor based in Vadodara, India. His significant contributions in the field of pharmaceuticals and biochemistry have led to the development of a crucial patent related to malic enzyme inhibitors. His work is particularly valuable in the therapeutic treatment of cancers.

Latest Patents

Gulamnizami holds one patent that focuses on novel compounds useful as malic enzyme (ME) inhibitors. This invention concerns processes for the preparation and use of these compounds in treating disorders mediated by ME, such as pancreatic ductal adenocarcinoma (PDAC) in humans. The novel compounds are characterized by a specific structural formula or acceptable variants, where components X, R, and Y are detailed within the patent specifications.

Career Highlights

Gulamnizami is associated with Sun Pharma Advanced Research Company Limited, a leading pharmaceutical organization. His role there emphasizes innovation in drug discovery and development, contributing to the advancement of medical treatments.

Collaborations

Throughout his career, Gulamnizami has collaborated with talented professionals such as Gaurav Sanjivkumar Sheth and Sabbirhusen Yusufbhai Chimanwala. These partnerships enhance the research environment and facilitate the exchange of valuable ideas and expertise.

Conclusion

Gulamnizami Abdulsattar Qureshi's contributions to the field of malic enzyme inhibitors reflect his commitment to addressing serious medical challenges. His patent work reveals the potential for novel therapies that could improve treatment outcomes for cancer patients, showcasing the vital role of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…